Esperion Therapeutics | DEF 14A: Definitive information statements
Esperion Therapeutics | ARS: Annual Report to Security Holders
Esperion Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Koenig Sheldon L.
Esperion Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Warren Eric
Esperion Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Foody Joanne M.
Esperion Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Halladay Benjamin
Esperion Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Looker Benjamin
Esperion Therapeutics | 10-K: Annual report
Esperion Therapeutics | 8-K: Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CVI Investments, Inc.(0%),Heights Capital Management, Inc.(0%)
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Two Seas Capital LP(6.8%),Two Seas Capital GP LLC(6.8%), etc.
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(0%),Deep Track Biotechnology Master Fund, Ltd.(0%), etc.
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Cubist Systematic Strategies, LLC(0.2%),Steven A. Cohen(0.2%), etc.
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.52%)
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BB Biotech AG(5.1%),Biotech Target N.V. N/A(5.1%)
Esperion Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BB Biotech AG(3.7%),Biotech Target N.V. N/A(3.7%)
Esperion Therapeutics | 8-K: Current report
Esperion Therapeutics | 424B5: Prospectus
Esperion Therapeutics | 8-K: Current report
No Data